Trial Profile
Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2016
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use